You are here

  • Home
  • Archive
  • Volume 66, Issue 7
  • Multidrug-resistant tuberculosis: resistance rates to first and reserve antituberculosis drugs in the UK in 2008/9 and the role of rapid molecular tests for drug resistance

Article Text

Article menu
Download PDFPDF
PostScript
Letter to the Editor
Multidrug-resistant tuberculosis: resistance rates to first and reserve antituberculosis drugs in the UK in 2008/9 and the role of rapid molecular tests for drug resistance
  1. S L Mitchell1,
  2. N Seoudi1,2,
  3. D C S Hutchison1,
  4. F A Drobniewski1
  1. 1National Mycobacterium Reference Laboratory, Barts and the London, Queen Mary's School of Medicine and Dentistry, London, UK
  2. 2Institute of Dentistry, Barts and the London, Queen Mary's School of Medicine and Dentistry, London, UK
  1. Correspondence to Dr F A Drobniewski, National Mycobacterium Reference Laboratory, Barts and the London, Queen Mary's School of Medicine and Dentistry, London, UK; f.drobniewski{at}qmul.ac.uk

https://doi.org/10.1136/thx.2010.148866

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    At the Health Protection Agency National Mycobacterium Reference Laboratory (HPA NMRL) between January 2008 and December 2009, we evaluated in patients with multidrug-resistant tuberculosis (MDRTB; isolates resistant to rifampicin and isoniazid) the rate of resistance to other first-line drugs (ethambutol and pyrazinamide) and to reserve drugs and the role of rapid …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.